Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Yang HS, LaFrance DR, Hao Y. Elemental Testing Using Inductively Coupled Plasma Mass Spectrometry in Clinical Laboratories. Am J Clin Pathol. 2021;156(2):167-175.

Lopez A, Patel S, Geyer JT, Racchumi J, Chadburn A, Simonson P, et al. Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Front Oncol. 2021;11:701318.

Satlin MJ, Chen L, Douglass C, Hovan M, Davidson E, Soave R, et al. Colonization With Fluoroquinolone-Resistant Enterobacterales Decreases the Effectiveness of Fluoroquinolone Prophylaxis in Hematopoietic Cell Transplant Recipients. Clin Infect Dis. 2021;73(7):1257-1265.

Punjani N, Flannigan R, Kang C, Khani F. Quantifying Heterogeneity of Testicular Histopathology in Men with Nonobstructive Azoospermia. J Urol. 2021;206(5):1268-1275.

Orr CE, Beneck D, Jessurun J, Qin L, Tyryshkin K, Yantiss RK, et al. High interobserver variability and frequent overdiagnosis of dysplasia in fundic gland polyps can be improved by detecting atypia on the surface epithelium and an abrupt transition to non-neoplastic cells. Histopathology. 2021.

Jessurun J. Helicobacter pylori: an evolutionary perspective. Histopathology. 2021;78(1):39-47.

Choi JJ, Westblade LF, Gottesdiener LS, Liang K, Li HA, Wehmeyer GT, et al. Impact of a Multiplex Polymerase Chain Reaction Panel on Duration of Empiric Antibiotic Therapy in Suspected Bacterial Meningitis. Open Forum Infect Dis. 2021;8(10):ofab467.

Napoli S, Cascione L, Rinaldi A, Spriano F, Guidetti F, Zhang F, et al. Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. Haematologica. 2021.

Hu Q, Poulose N, Girmay S, Helevä A, Doultsinos D, Gondane A, et al. Inhibition of CDK9 activity compromises global splicing in prostate cancer cells. RNA Biol. 2021:1-8.

Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, et al. Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Adv Mater. 2021:e2100096.